Aprobación de la gestión 2022: Agencia Europea de Medicamentos

Texto tal como lo publica el PE, en inglés.

1. Enmienda 1 · Propuesta de ResoluciónRechazada

   Paragraph 2 a (new)

   Presentada por Ryszard Czarnecki, Cristian Terheş · ECR

   Añadido: 2 a. Notes with concern that in 2021 and 2022 around 86 % of EMA’s budget was funded by private pharmaceutical firms; highlights that such a percentage can appear incompatible with independent decision making, and that the EMA’s action cannot be qualified as driven by public interest only1a; 1a https://www.ema.europa.eu/en/about-us/how-we-work/governance-reporting/funding

2. Enmienda 2 · Propuesta de ResoluciónRechazada

   Paragraph 5 a (new)

   Presentada por Ryszard Czarnecki, Cristian Terheş · ECR

   Añadido: 5 a. Notes with concern that in 2022 two new COVID-19 vaccines were approved for use throughout the Union and in total seven COVID-19 vaccines were authorised;

3. Enmienda 3 · Propuesta de ResoluciónRechazada

   Paragraph 7 a (new)

   Presentada por Ryszard Czarnecki, Cristian Terheş · ECR

   Añadido: 7 a. Notes with concern that during the COVID pandemic, all the vaccines available in the Member States were in phase 3 clinical trials (phase of experimentation on humans);

4. Enmienda 4 · Propuesta de ResoluciónRechazada

   Paragraph 7 b (new)

   Presentada por Ryszard Czarnecki, Cristian Terheş · ECR

   Añadido: 7 b. Regrets that EMA’s assessment of the side effects of the COVID-19 vaccines lacked transparency and was overdue and overly lenient with regard to the decisions taken or alerts issued by the national authorities;